Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9618072 | 1.00 | ALOX15 (0.49) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL9618071 | 1.00 | ALOX15 (0.49) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL11842673 | 0.89 | ALOX15 (0.45) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL11849438 | 0.89 | ALOX15 (0.45) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL11858937 | 0.88 | ALDH1A1 (0.50) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL11858941 | 0.88 | ALDH1A1 (0.50) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL28035603 | 0.86 | ALDH1A1 (0.37) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL10464133 | 0.85 | ALDH1A1 (0.39) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL10464085 | 0.85 | ALDH1A1 (0.36) | ALOX15ALDH1A1TDP1LMNACYP3A4 | |
| SCHEMBL10464084 | 0.85 | ALDH1A1 (0.36) | ALOX15ALDH1A1TDP1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7381747-B2 | Alpha 2 delta ligands for post-traumatic stress disorder | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381747-B2 | Alpha 2 delta ligands for post-traumatic stress disorder | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1840117-A1 | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | Warner-Lambert Company LLC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | ALOX15 390/4885ALDH1A1 775/4885TDP1 1748/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | ALOX15 496/4885ALDH1A1 1174/4885TDP1 3116/4885 |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | ALOX15 390/4885ALDH1A1 775/4885TDP1 1748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.